New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
18:20 EDTAGNAllergan confirms FDA approval of Natrelle 410 breast implants
Allergan announced that the company has received approval from the U.S. FDA to market the Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery. The Natrelle 410 shaped gel implant is designed to mimic the slope of the breast and is filled with a highly cohesive silicone gel, which is intended to enable the implant to hold its shape over time while remaining soft to the touch.
News For AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
08:34 EDTAGNAllergan says FDA approves Natrelle Inspira breast implants
Subscribe for More Information
February 20, 2015
07:08 EDTAGNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
07:40 EDTAGNActavis price target raised to $352 from $300 at Canaccord
Subscribe for More Information
February 18, 2015
16:46 EDTAGNOn The Fly: Closing Wrap
Subscribe for More Information
12:31 EDTAGNOn The Fly: Midday Wrap
Subscribe for More Information
09:48 EDTAGNActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
07:50 EDTAGNActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTAGNActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:34 EDTAGNActavis sees Allergan transaction completed in late Q1 or early Q2

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use